Comparing the current results to its competitors, Intellipharmaceutics International Inc reported Revenue increase in the 4 quarter 2022 by 0 % year on year. The revenue growth was below Intellipharmaceutics International Inc 's competitors' average revenue growth of 25.54 %, achieved in the same quarter.
Intellipharmaceutics International Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 44.84 %
Publicly Traded Peers of Intellipharmaceutics International Inc
Viatris Inc Share Performance
+1.48%
This Quarter
Viatris Inc
Profile
Viatris Inc operates as a global pharmaceutical company, specializing in the development, manufacturing, and distribution of a wide range of generic and branded medicines, as well as biosimilars.
Biophytis SA is a biotechnology company that focuses on developing innovative therapeutics for age-related diseases, with a specific emphasis on degenerative eye diseases and muscle wasting conditions. They leverage their expertise in biology and clinical development to discover and advance targeted drug candidates, aiming to address the unmet medical needs of patients in these areas.
Amneal Pharmaceuticals Inc operates as a fully integrated pharmaceutical company, primarily focused on the development, manufacturing, and distribution of generic and specialty pharmaceutical products. Their business model revolves around identifying market opportunities, conducting research to develop cost-effective formulations, and leveraging their expansive manufacturing capabilities to produce and distribute a wide range of pharmaceuticals to customers globally. Additionally, they aim to provide high-quality products at competitive prices while continuously investing in research and development to expand their product portfolio.
Amphastar Pharmaceuticals Inc's business model revolves around developing, manufacturing, and marketing specialty pharmaceutical products. The company focuses on niche markets and primarily produces finished dosage form and active pharmaceutical ingredients (APIs) for injectable, inhalation, and intranasal delivery systems. Amphastar aims to provide innovative and cost-effective solutions for complex therapeutic needs, while maintaining regulatory compliance and ensuring the highest standard of quality.
Sources:
Intellipharmaceutics International Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Intellipharmaceutics International Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
